Blurbs

Sarepta Therapeutics (SRPT) Gets a Buy Rating from RBC Capital

In a report issued on July 7, Brian Abrahams from RBC Capital maintained a Buy rating on Sarepta Therapeutics (SRPTResearch Report), with a price target of $156.00. The company’s shares closed last Friday at $80.47.

According to TipRanks.com, Abrahams is a 1-star analyst with an average return of -1.0% and a 46.5% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $123.15, implying a 55.1% upside from current levels. In a report issued on June 23, Robert W. Baird also maintained a Buy rating on the stock with a $110.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $101.24 and a one-year low of $61.28. Currently, Sarepta Therapeutics has an average volume of 782.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Read More on SRPT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos